Latest Regulatory News

GR Engineering Services Limited has updated its dividend details for the first half of FY2025, declaring a fully franked dividend of 12 cents per share and setting the Dividend Reinvestment Plan price at AUD 3.897 with a 2.5% discount.

American Uranium Limited is set to commence hydrogeologic testing and resource expansion drilling at its Lo Herma uranium project in Wyoming during the fourth quarter of 2025, aiming to boost its mineral resource base and support upcoming scoping studies.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

Andromeda Metals' latest Scoping Study reveals a compelling economic case for its innovative High Purity Alumina (HPA) production technology, highlighting strong returns and a significant carbon emissions advantage. The project aims to meet soaring global demand with a 10,000 tonne per annum facility in South Australia.

Blue Star Helium Limited reports steady progress on its Galactica helium project in Colorado, with first helium production on track for December 2025 and full ramp-up expected through 2026.

Western Gold Resources Limited has had its trading suspension lifted following the release of initial assay results from its Duke Gold project and a response to an ASX price and volume query.

Tempest Minerals has secured regulatory approval to begin Phase I drilling at its Halo prospect within the Yalgoo Project, targeting iron, copper, and gold. A heritage survey with the Badimia People is currently in progress, marking a key step toward unlocking the site's potential.

Highfield Resources has requested a voluntary suspension of its shares on the ASX to complete a capital raising, with trading expected to resume by 23 September 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Prospech Limited’s PRSO securities have been suspended from trading pending compliance with ASX rules, raising questions about the company’s regulatory standing.

Mont Royal Resources Ltd (ASX – MRZ) has lodged a prospectus to raise between A$8 million and A$10 million through a share offer priced at A$0.20 each, coinciding with a proposed merger with Commerce Resources Corp (TSXV – CCE). The combined entity aims to become a leading Quebec-focused critical minerals developer.